Pathological complete response following systemic therapy with carboplatin-paclitaxel plus pembrolizumab for initially unresectable mismatch repair-deficient advanced endometrial cancer: two case reports
{{output}}
Background: Mismatch repair-deficient (dMMR) endometrial cancer is highly sensitive to immune checkpoint inhibition. Although pembrolizumab combined with carboplatin and paclitaxel is now a first-line standard treatment for advan... ...
